Skip to content

Author

C. Correll

We have 11 of 1,545 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Multidimensional transdiagnostic inventory of psychopathology: development and initial validation

Traditional diagnostic systems, such as the DSM-5 and ICD-11, suffer from well-documented limitations, including high comorbidity rates, arbitrary diagnostic thresholds, and within-disorder heterogeneity. Consequently, the field is evolving towards hierarchical, transdiagnostic, dimensional models of psychopathology. T...

Mark A. Blais, Hannah Cai, Till J. Adam et al. · 0 citations
Open access Sep 2026

620. Facilitating gender equity in neuropsychopharmacological clinical research

Abstract Background Depressive and anxiety disorders are significantly more common in women than in men [1]. Despite higher prevalence, there is paucity of published evidence on the evaluation of efficacy and safety of drugs used for these conditions in women [2]. Various guidelines recommend inclusion of women and min...

C. Correll, A. Fagiolini, M. P. Mariano et al. · 0 citations
Open access Sep 2026

Sex-Specific Changes in Outpatient and Inpatient Care for Depressive Disorders in Children and Adolescents in Germany During the COVID-19 Pandemic.

The data showed declines in the prevalence and incidence of depressive disorders, potentially reflecting care avoidance or reduced treatment capacities, particularly among boys, and differences emerged in service utilization by care provider.

Stephan Zillmer, Jule Leickert, Christian J. Bachmann et al. · 0 citations
Open access Aug 2026

Psychometric validation of research domain criteria, general health, and clinical-psychosocial parts of the minimum dataset of the German Center for Mental Health—informing a Delphi process

This study evaluated the latent structure and conceptual validity of the Research Domain Criteria (RDoC), General Health, and Clinical/Psychosocial clusters of the German Center for Mental Health (DZPG) Minimum Data Set (MDS). It aimed to determine whether these clusters represent interpretable constructs and demonstra...

Bernd R. Förstner, S. Böttger, Timm Seegert et al. · 0 citations
Review Open access Oct 2026

Cannabis use and subsequent onset of manic symptoms and bipolar disorder: A systematic review and meta-analysis.

BACKGROUND Bipolar disorder is a disabling psychiatric condition affecting approximately 2% of the population, for which identifying modifiable risk factors prior to illness onset is a research priority. Cannabis use is highly prevalent, yet its role in the development of bipolar-spectrum outcomes remains unclear. Prev...

Cecilia Sanjuan-Ortiz, Paula Querol, C. Aymerich et al. · 0 citations
Review Open access Aug 2026

Reconceptualizing Schizophrenia through a Patient-Oriented Perspective: a Systematic Review and Qualitative Meta-Synthesis

Abstract Background and Hypothesis Schizophrenia spectrum disorders are typically described using positive and negative symptoms, yet standard diagnostic systems may not reflect the full range of how individuals experience the disorder. We hypothesized that synthesizing first-person accounts would yield a broader, clin...

S. F. Aprile, Alessandro Rodolico, Djordje Basic et al. · 0 citations
Review Open access Sep 2026

Well-being differences and changes in people with somatic and psychiatric disorders or multimorbidities: modelling COVID-19 as a global natural experiment of stress vulnerability

High-risk disorder profiles for lower well-being and well-being decline under stress are identified by modelling COVID-19 as a natural experiment and non-linear/supra-additive adverse outcomes beyond single disorders are identified.

T. Adam, Trevor Thompson, Fabiola H. Peroz et al. · 0 citations
Meta-analysis Open access Aug 2026

Positive and Negative Symptoms Changes in Schizophrenia Patients on Antipsychotic Treatment: a Systematic Review and Dose–Response Meta-analysis

The effects of antipsychotics on negative symptoms are smaller than those on positive symptoms, at least in studies of mostly acutely exacerbated patients, and the dose–response curves for both types of symptoms are relatively parallel.

Xiao Lin, S. Siafis, Jing Tian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.